EditorialsSaved From Sepsis: Can Immunotherapy Improve Acute and Postacute Outcomes?*Cawcutt, Kelly A. MD, MS; Kalil, Andre C. MD, MPH, FCCMAuthor Information Department of Internal Medicine, Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, NE *See also p. 632. Dr. Cawcutt received funding form Becton Dickinson/Bard, and she disclosed off-label investigational product use antiprogrammed cell death ligand-1 therapy for sepsis. Dr. Kalil has disclosed that he does not have any potential conflicts of interest. Critical Care Medicine: May 2019 - Volume 47 - Issue 5 - p 733-735 doi: 10.1097/CCM.0000000000003702 Buy Metrics Copyright © 2019 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.